Pulse lineResearch With Heart Logo

ARIC Publications

Filters: Keyword is 1-Alkyl-2-acetylglycerophosphocholine Esterase  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Gregson JM, Freitag DF, Surendran P, et al. "Genetic invalidation of Lp-PLA as a therapeutic target: Large-scale study of five functional Lp-PLA-lowering alleles." Eur J Prev Cardiol. 2017;24(5):492-504.
L
Pokharel Y, Sun W, Polfus LM, et al. "Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study." Atherosclerosis. 2015;241(2):641-8.
Garg PK, Norby FL, Polfus LM, et al. "Lipoprotein-associated phospholipase A and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC)." Atherosclerosis. 2018;268:12-18.
Nambi V, Hoogeveen RC, Chambless L, et al. "Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study." Stroke. 2009;40(2):376-81.
Folsom AR, Lutsey PL, Roetker NS, Ballantyne CM, Hoogeveen RC, Rosamond WD. "Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study." Thromb Res. 2013;132(1):44-6.
Ballantyne CM, Hoogeveen RC, Bang H, et al. "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study." Circulation. 2004;109(7):837-42.
Ballantyne CM, Hoogeveen RC, Bang H, et al. "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study." Arch Intern Med. 2005;165(21):2479-84.